IgGenix, Inc. is a biotechnology company focused on developing innovative antibody therapeutics for the treatment of food and other severe allergies. Founded in 2019 and based in South San Francisco, California, the company specializes in isolating and transforming allergen-specific IgE antibodies into IgG antibodies. This process aims to alleviate and prevent allergic reactions by suppressing the allergic cascade. IgGenix captures and analyzes rare human B cells that produce allergen-binding antibodies and engineers these cells to enhance their immune-modulating properties. By addressing critical needs in the medical industry, IgGenix seeks to provide effective solutions for life-threatening allergic reactions.
Equii is a food technology company that discovers highly nutritious sources of microbial proteins that are used to ferment grains and produce high-protein grain flours. Founded in 2021 by Monica Bhatia, Equii is based in San Ramon, California.
Prellis Biologics is building human tissues for drug development, and ultimately, developing human organs for transplantation. Bioprinting vascularized human tissue and organs will revolutionize healthcare. Prellis Biologics' technology leverages massive gains in print speed and resolution to break the microvasculature barrier.
Genecis is an early-stage organic waste processing startup that uses biotechnology to convert waste into biodegradeable plastics and other high value materials. Genecis is headquartered in Scarborough, Canada.
Relation Therapeutics is a biotechnology company focused on advancing drug discovery and development. It utilizes human genetics and clinical omics data, alongside patient-derived tissue samples, to identify and validate therapeutic programs. The company employs machine learning to explore the relationships between genes, proteins, and drugs, generating insights that have real translational validity. By combining single-cell multi-omics from patient tissues with functional assays, Relation Therapeutics aims to deepen the understanding of biological processes in human health and disease. This approach enables healthcare providers to discover and develop novel treatments, particularly in areas with unmet medical needs.
Developer of a deep learning platform intended to deliver medicines of transformational efficacy for patients. the company platform delivers transformational medicines through 3D deep learning and cutting-edge drug discovery technologies, enabling doctors in treating undruggable disease targets.
Developer of drug discovery platform designed for radically accelerating small molecule drug discovery and finding pharmaceutical compounds for medically important targets. The company's technology rapidly analyzes compounds by combining machine learning with DNA-encoded libraries to generate enormous amounts of useful data and parallel biochemical experiments using proprietary artificial intelligence (AI) models, enabling researchers to develop new drugs.
Ultima Genomics, founded in 2016 and based in Newark, California, specializes in genome-scale sequencing technology aimed at providing analytical services to enterprises. The company employs an innovative approach using an open substrate that creates a large, low-cost reaction surface, allowing for billions of reads without the need for expensive flow cells or complex fluidics. By integrating specialized sequencing hardware with machine learning, Ultima Genomics ensures reproducible and accurate results, enabling clients to obtain genomic reports rapidly and efficiently. This technology not only enhances the scale of genomic information but also significantly reduces the costs associated with sequencing, thereby facilitating advancements in biology and improvements in human health.
Derived from exotic plants, protein sweeteners are rare compounds that provide an amazing taste without the calories.
Mirvie is a biotech company that creates precise, actionable, and non-invasive tests for maternal-fetal health. The company delivers insights to moms and families to make pregnancy safe. It was founded in 2018 by Maneesh Jain and is headquartered in South San Francisco, California, United States.
VitroLabs, Inc. is a San Jose, California-based startup specializing in 3D tissue engineering through innovative stem cell technologies. Founded in 2016, the company focuses on developing scalable platforms for creating authentic biomaterials, allowing for the production of luxury lab-grown leather and fur without the need to raise or slaughter animals. By leveraging advancements in stem cell research and biomaterials, VitroLabs provides sustainable alternatives for fashion brands and interior product manufacturers, promoting ethical practices in the industry.
Turn Biotechnologies is a Stanford spinout developing therapies to effectively return mature differentiated cells to a dramatically younger state leaving their differentiated identity unaltered. Turn Biotechnologies surpasses traditional approaches based on single gene/pathway manipulations and tackles the multifaceted manifestation of cellular age at the organ, tissue, and organismal level to extend the healthspan of people. As a result, age is reset by epigenetically reprogramming cells.
Leaft Foods is a producer of plant-based protein focused on promoting both environmental and human health. The company utilizes abundant sources of natural protein, particularly extracting protein from lush green leaves through a paddock-to-production process. This approach allows Leaft Foods to provide food companies with sustainable and nutritious leaf protein ingredients, facilitating the creation of edible food products that align with growing consumer demand for plant-based options. Operating within New Zealand's pasture-based agricultural economy, Leaft Foods demonstrates the viability of its innovative practices in both nutrition and sustainability.
Volta Labs, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on engineering and developing tools for biological automation. Founded in 2018, the company specializes in creating scalable automation solutions for genetic engineering, aiming to enhance efficiency and precision in biological research and applications.
Cellino Biotech, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2017. It specializes in intracellular delivery lasers and nanotechnology specifically for gene editing applications. The company has developed an AI-guided laser editing platform that automates the generation of personalized, autologous cell therapies, significantly reducing the development time of engineered cells from years to weeks. By integrating advanced tools from optics, biology, and computation, Cellino makes stem cell differentiation a digital process, allowing healthcare providers to efficiently produce functionally mature cells at scale. This innovative approach aims to enhance the accessibility of life-saving medicines for patients.
Developer of drug discovery platform designed for radically accelerating small molecule drug discovery and finding pharmaceutical compounds for medically important targets. The company's technology rapidly analyzes compounds by combining machine learning with DNA-encoded libraries to generate enormous amounts of useful data and parallel biochemical experiments using proprietary artificial intelligence (AI) models, enabling researchers to develop new drugs.
NextVivo is a biotech company developing an immune organoid technology platform to transform the future of drug development. Its mission is to accelerate the development of safer, more effective therapies that are generated and tested in immune-competent human-derived models.
Nabla is an autoreverse platform that enables the rapid discovery of previously unattainable protein variants with supernatural qualities.Nabla Bio makes new medicines and improve nutrition by engineering novel proteins.
Fountain Therapeutics is discovering and developing treatments for aging-associated diseases.
Fountain Therapeutics was founded with the belief that a future in which we live healthier lives longer is more desirable than one in which the company continues to be afflicted by the disease of aging. The company builds a transformative model of aging that re-creates many of the complex hallmark features of aging but in a laboratory dish. We are combining this powerful cellular model with the latest in artificial intelligence and computer vision to develop a disruptive unbiased platform for the identification of novel targets and potential therapeutics.
Viome, Inc. is a biotechnology company based in Bellevue, Washington, that specializes in wellness monitoring through at-home clinical-grade testing kits. Founded in 2016, the company combines analyses of blood, urine, saliva, and stool samples to create detailed profiles of an individual's biochemistry and gut microbiome. Utilizing proprietary RNA sequencing technology, Viome assesses the microbial communities in the digestive system and provides users with personalized insights related to their health. The findings are integrated into a smartphone application that offers tailored recommendations for diet and lifestyle adjustments aimed at preventing and reversing chronic diseases. Viome markets its products through various distributors and online platforms, operating as a subsidiary of BlueDot LLC.
Akualogix is an agrifood tech start-up that produces shrimp, whitefish, and seaweeds in high-tech five-story farming systems. The company uses advanced technologies and sustainable practices in urban, vertical aquafarms to produce fresh shrimp, fish, and umibudo. Its vertical oceans combine multi-trophic biology with advanced digital technologies in modular growing habitats efficiently stacked in a vertical tower. Akualogix was established in 2020 and is based in Singapore.
Cambridge Glycoscience is a biotechnology company based in London, United Kingdom, founded in 2017. The company specializes in developing sugar-free ingredients for the food industry, focusing on creating natural food components derived from agricultural resources. Their innovative products enable food manufacturers to reduce sugar content, enhance fiber levels, and improve gut health-promoting qualities in food items. By leveraging biotechnology, Cambridge Glycoscience aims to support healthier eating options and contribute to the evolving landscape of food production.
Developer of veterinary pharmaceuticals designed to improve the health span and lifespan of dogs. The company's drugs delay the onset of age-related diseases like cancer, heart diseases and metabolic diseases, enabling dogs to live healthier, longer lives.
Opentrons is a company focused on developing pipetting robot technology to automate laboratory experiments. By utilizing open-source principles and programming in Python, Opentrons creates automated lab equipment that streamlines various scientific processes. Their product offerings encompass lab robots, workstations, hardware modules, consumables, reagents, and labware, all designed to enhance the efficiency and accuracy of research. This automation helps scientific researchers reduce human error and expedite their experimental workflows, making lab work faster and less labor-intensive.
Karma Biotechnologies, Inc. develops therapies for autoimmune diseases. It offers Xavines, a therapeutic to treat autoimmunity, allergies, and food sensitivities. Karma Biotechnologies, Inc. was incorporated in 2019 and is based in Los Angeles, California.
Known Medicine is looking to take the experimentation of how tumors respond to cancer drugs out of the patient’s body and into the lab. The startup breaks down tumor samples into micro tumors, which they treat separately inside specialized micro-environments with different methods and see what works best.
Encellin, Inc. is a biotechnology company based in San Francisco, California, founded in 2015. It specializes in developing innovative cell-based therapeutics, particularly focusing on a novel thin-film cell encapsulation device. This device utilizes advanced thin-film cell delivery technology, which encapsulates and replaces cells, allowing the enclosed cells to operate as smart molecular factories. Encellin's primary mission is to provide effective treatments for patients with chronic diseases, with an initial emphasis on Type 1 diabetes. The company is committed to advancing next-generation therapies through the expertise of its dedicated team.
Encellin, Inc. is a biotechnology company based in San Francisco, California, founded in 2015. It specializes in developing innovative cell-based therapeutics, particularly focusing on a novel thin-film cell encapsulation device. This device utilizes advanced thin-film cell delivery technology, which encapsulates and replaces cells, allowing the enclosed cells to operate as smart molecular factories. Encellin's primary mission is to provide effective treatments for patients with chronic diseases, with an initial emphasis on Type 1 diabetes. The company is committed to advancing next-generation therapies through the expertise of its dedicated team.
Deep Genomics Inc. is an artificial intelligence therapeutics company that focuses on developing individualized genetic medicines. Founded in 2014 and based in Toronto, Canada, the company utilizes advanced AI systems to enhance various stages of drug discovery and development, including target identification, lead optimization, toxicity evaluation, and trial design. Deep Genomics specializes in creating oligonucleotide therapies that address the genetic causes of diseases at the RNA and DNA levels. Its innovative AI-powered platform analyzes RNA biology to uncover new therapeutic targets and mechanisms that traditional methods cannot access, enabling the development of treatments for rare metabolic, ophthalmologic, and neurodegenerative disorders. The company recruits top talent in genomics, drug development, and AI to drive its mission of revolutionizing drug discovery.
IgGenix, Inc. is a biotechnology company focused on developing innovative antibody therapeutics for the treatment of food and other severe allergies. Founded in 2019 and based in South San Francisco, California, the company specializes in isolating and transforming allergen-specific IgE antibodies into IgG antibodies. This process aims to alleviate and prevent allergic reactions by suppressing the allergic cascade. IgGenix captures and analyzes rare human B cells that produce allergen-binding antibodies and engineers these cells to enhance their immune-modulating properties. By addressing critical needs in the medical industry, IgGenix seeks to provide effective solutions for life-threatening allergic reactions.
Ochre Bio develops genomic medicines to rejuvenate donors' livers before transplant, so that everyone who needs a new liver gets one.
They use genomics to find and shut down over-active genes driving disease and then go directly to testing therapies in discarded donor livers that keep alive outside of the body.
Ochre Bio is within the heart of Oxford’s biotech innovation hub. Their scientific roots can be traced back to over 15 years leading liver genomics research and experience in bringing advanced therapies to market.
Clear Labs, Inc. is a food analytics company based in Menlo Park, California, founded in 2013. The company offers a comprehensive food analytics platform that utilizes next-generation sequencing to analyze the molecular contents of foods and ingredients. This platform provides food manufacturers, suppliers, and retailers with crucial transparency across supply chains, testing products for authenticity, contaminants, allergens, and various other factors such as GMOs, heavy metals, and nutrition. Clear Labs also focuses on simplifying complex diagnostics for clinical and applied markets, combining DNA sequencing, robotics, and cloud-based analytics to improve accuracy and accelerate outcomes. By delivering insights into food safety and quality, Clear Labs aims to enhance understanding and management of potential health risks associated with food products and emerging pathogens.
Overture Life, Inc. is a New York-based company that specializes in developing robotic technologies for in vitro fertilization (IVF) applications. Founded in 2017, Overture Life aims to transform embryology through its innovative reproduction automation technology. The company's products focus on automating key processes in IVF, including devices for automated cryopreservation and embryo testing services. These advancements enable fertility clinics to identify viable embryos prior to implantation, thereby assisting individuals and couples in their efforts to conceive.
Apton Biosystems, Inc., founded in 2012 and based in Pleasanton, California, operates within the biotechnology sector, focusing on innovative solutions for genetic analysis. The company has developed a high-throughput and low-cost sequencing platform that enhances the availability of genetic testing, facilitating biomarker discovery, early disease detection, and therapeutic monitoring. Apton Biosystems reimagines optical systems for sequencing and single-molecule protein detection, utilizing super-resolution technology to evaluate closely spaced molecules. This approach enables the healthcare sector to create well-defined nanostructures, addressing spatial challenges and advancing high-density sequencing and protein detection capabilities. Through these advancements, Apton Biosystems contributes to the fields of preventive health and precision medicine.
Turn Biotechnologies is a Stanford spinout developing therapies to effectively return mature differentiated cells to a dramatically younger state leaving their differentiated identity unaltered. Turn Biotechnologies surpasses traditional approaches based on single gene/pathway manipulations and tackles the multifaceted manifestation of cellular age at the organ, tissue, and organismal level to extend the healthspan of people. As a result, age is reset by epigenetically reprogramming cells.
Pendulum Therapeutics Inc., a microbiome company, produces microbiome-targeted medical probiotics. It offers Pendulum Glucose Control, a medical probiotic for the dietary management of type 2 diabetes. The company also develops prebiotics to help feed the probiotic strains. It sells its products online. Pendulum Therapeutics Inc. was formerly known as Whole Biome Inc. and changed its name to Pendulum Therapeutics Inc. in July 2019. The company was incorporated in 2012 and is based in San Francisco, California.
Briefcase Biotec develops KiloBaser, a Nespresso machine of DNA synthesis - enabling cutting edge research without detours. KiloBaser is a device for printing short synthetic DNA sequences. It enables individual scientists to easily produce the DNA they need on their desktops, while speeding up production of the basics for all genetic engineering and synthetic biology research and development. Headquartered in Graz, Steiermark, KiloBaser was founded in 2013 by Martin Jost and Alexander Murer.
Inflammatix, Inc. is a molecular diagnostics company based in Burlingame, California, established in 2016. The company specializes in developing rapid tests that analyze the immune system to address significant clinical and public health challenges, particularly in the diagnosis of acute bacterial and viral infections, as well as sepsis. Utilizing patent-pending biomarkers exclusively licensed from Stanford University, Inflammatix aims to create clinically actionable results through proprietary machine-learning algorithms. In addition to its focus on acute infections and sepsis, the company is expanding its diagnostics pipeline to include tests for tropical infections, autoimmune diseases, transplant rejection, and other medical conditions, ultimately assisting healthcare providers in making informed diagnostic decisions.
Bionaut Labs is a biotechnology company that specializes in developing an intra-tissue navigation platform using nano and micro-robots for medical applications. Founded in 2016 and headquartered in California, Bionaut Labs focuses on creating a delivery mechanism that allows for anatomically precise navigation within the body. The company's innovative micro-robotic technology is designed to access any anatomical location, enabling medical professionals to perform complex surgical procedures remotely and without external incisions. This advancement is achieved through an advanced remote control and imaging system that accurately guides the robots to their targets, monitors their progress, and triggers the release of therapeutic payloads at the appropriate locations and times.
EGenesis Inc. is a biotechnology company based in Cambridge, Massachusetts, with an additional office in New York. Founded in 2015, the company specializes in gene editing and genome engineering, focusing on the development of human-compatible organs, tissues, and cells for transplantation. EGenesis employs advanced gene editing techniques to create transplantable cells and solid organs, specifically targeting therapeutic applications in kidney and islet cell transplantation. By leveraging its innovative platform, the company aims to transform the field of organ transplantation, providing safe and effective solutions for patients with life-threatening diseases globally.
Cambridge Glycoscience is a biotechnology company based in London, United Kingdom, founded in 2017. The company specializes in developing sugar-free ingredients for the food industry, focusing on creating natural food components derived from agricultural resources. Their innovative products enable food manufacturers to reduce sugar content, enhance fiber levels, and improve gut health-promoting qualities in food items. By leveraging biotechnology, Cambridge Glycoscience aims to support healthier eating options and contribute to the evolving landscape of food production.
Cellino Biotech, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2017. It specializes in intracellular delivery lasers and nanotechnology specifically for gene editing applications. The company has developed an AI-guided laser editing platform that automates the generation of personalized, autologous cell therapies, significantly reducing the development time of engineered cells from years to weeks. By integrating advanced tools from optics, biology, and computation, Cellino makes stem cell differentiation a digital process, allowing healthcare providers to efficiently produce functionally mature cells at scale. This innovative approach aims to enhance the accessibility of life-saving medicines for patients.
Developer of immunity-boosting proteins designed to improve the lives of people who suffer from food allergies and gluten-related disorders. The company's technology uses artificial intelligence, immunology, computational biology, and protein engineering to make safe proteins that do not trigger an immune response, enabling physicians to prescribe to people products that are safe to consume.
Earli is focused on transforming cancer detection and treatment by developing innovative technologies that enable early identification of tumors. The company specializes in creating synthetic biopsies, which are designed to induce cancer cells to produce non-human synthetic biomarkers. These biomarkers can be detected in biological samples such as blood, urine, or breath, allowing for the visualization of tumors that are typically too small to identify in traditional screenings. By leveraging these programmable genetic constructs, Earli aims to provide real-time data on cancer presence and progression, facilitating personalized treatment approaches and improving the chances of successful intervention. Overall, Earli's mission is to make the experience of cancer more manageable by ensuring timely detection and response.
Rubedo Life Sciences, Inc. is a biopharmaceutical company based in Sunnyvale, California, focused on developing therapies for age-related diseases by targeting senescent cells. Incorporated in 2018, the company utilizes its ALEMBIC drug discovery platform to create a pipeline of therapeutic candidates that selectively eliminate senescent cells, as well as pro-inflammatory and pro-fibrotic cell populations resulting from cellular stress and damage. By promoting selective apoptosis in aged or pathological tissues, Rubedo aims to regenerate tissues, improve the function of healthy cells, and ultimately extend the health span of patients. The company is dedicated to addressing the challenges posed by age-related conditions through innovative therapeutic solutions.
Advanced Chemotherapy Technologies is a healthcare company that is developing breakthrough combination drug-device technologies for treating pancreatic cancer.
Siolta Therapeutics is a developer of human microbiome therapeutics intended to prevent and treat inflammatory diseases. The company leverages its deep knowledge of the developing gut microbiome and its role in promoting immune tolerance to develop targeted microbial therapeutics and companion diagnostics for the prevention and treatment of inflammatory diseases, enabling medical researchers to harness information from human microbiome studies to design next-generation microbial therapeutics to prevent inflammatory processes.
SiPhox Inc. is a company based in Cambridge, Massachusetts, specializing in the design and manufacture of disposable testing kits for COVID-19 and other diseases. Founded in 2020, SiPhox offers a handheld testing device that utilizes advanced technology to perform RNA, DNA, and protein testing. The company's testing kits incorporate multiplexing of RNA, antibody, and antigen tests on a single silicon photonic chip, enhanced by plasmon resonance and silicon photonic resonator readout. This innovative approach allows users to safely conduct tests for various diseases in both point-of-care and at-home settings, using disposable SiPhox Biosensor cartridges and the SiPhox PROBE.
IgGenix, Inc. is a biotechnology company focused on developing innovative antibody therapeutics for the treatment of food and other severe allergies. Founded in 2019 and based in South San Francisco, California, the company specializes in isolating and transforming allergen-specific IgE antibodies into IgG antibodies. This process aims to alleviate and prevent allergic reactions by suppressing the allergic cascade. IgGenix captures and analyzes rare human B cells that produce allergen-binding antibodies and engineers these cells to enhance their immune-modulating properties. By addressing critical needs in the medical industry, IgGenix seeks to provide effective solutions for life-threatening allergic reactions.
Derived from exotic plants, protein sweeteners are rare compounds that provide an amazing taste without the calories.
Menten AI, Inc. is an early-stage drug discovery company based in San Francisco, California, with an additional location in Toronto, Canada. Founded in 2018, the company focuses on developing protein-based drugs and enzymes using advanced technologies, specifically machine learning and quantum computing. Menten AI addresses the complex challenge of designing proteins, which can adopt numerous shapes, by leveraging quantum computing to represent multiple protein states simultaneously. This innovative approach allows for more efficient identification of optimal protein designs. The company has achieved significant milestones, including creating the world’s first peptide designed on a quantum computer, and is currently working on peptide therapeutics aimed at treating oncology and neurodegeneration, as well as enzymes for various industrial applications.
Clear Labs, Inc. is a food analytics company based in Menlo Park, California, founded in 2013. The company offers a comprehensive food analytics platform that utilizes next-generation sequencing to analyze the molecular contents of foods and ingredients. This platform provides food manufacturers, suppliers, and retailers with crucial transparency across supply chains, testing products for authenticity, contaminants, allergens, and various other factors such as GMOs, heavy metals, and nutrition. Clear Labs also focuses on simplifying complex diagnostics for clinical and applied markets, combining DNA sequencing, robotics, and cloud-based analytics to improve accuracy and accelerate outcomes. By delivering insights into food safety and quality, Clear Labs aims to enhance understanding and management of potential health risks associated with food products and emerging pathogens.
Genalyte, Inc. is a clinical and diagnostic life science company based in San Diego, California, specializing in rapid diagnostic testing solutions. Founded in 2007, Genalyte has developed an innovative technology platform that utilizes silicon photonic biosensors to quantify biomolecular interactions, such as those between antibodies and proteins. This platform, known as the Maverick, allows for the direct measurement of protein binding and nucleic acid hybridization. Genalyte's technology is employed by healthcare providers, pharmaceutical companies, and academic researchers to monitor autoimmune diseases, screen for cancer biomarkers, detect anti-drug antibodies, and test for infectious agents, including Ebola. The company aims to enhance patient care by enabling rapid diagnostics, with tests typically completed in under thirty minutes, and providing mobile laboratory solutions for real-time diagnostics.
E25Bio specializes in the development of rapid diagnostic tests for epidemic fever viruses. It is dedicated to preventing severe downstream health outcomes with the use of mobile, fast, real-time reporting to create unprecedented large datasets to guide informed and timely responses for the control of disease spread.
The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Karius, Inc. is a life sciences company dedicated to generating genomic insights for infectious diseases. It offers the Karius Test, a non-invasive blood test that utilizes sequencing of microbial cell-free DNA to identify and quantify various pathogens, including bacteria, DNA viruses, fungi, and parasites. This test is particularly useful for diagnosing complicated pneumonia, infections in immunocompromised patients, and endocarditis. Karius also provides laboratory services for pathogen biomarker detection tailored for biopharmaceutical companies. Founded in 2014, the company is based in Redwood City, California, with an additional office in Menlo Park. Its laboratory holds CLIA certification and CAP accreditation, allowing it to conduct high-complexity clinical laboratory testing to support rapid clinical decision-making.
Q Bio, Inc. is a healthcare technology company that has developed a clinically relevant whole body analytics platform aimed at providing comprehensive health assessments. Founded in 2015 and based in Redwood City, California, Q Bio combines advanced non-invasive imaging, genetics, biochemistry, vital signs, and an individual's medical history to create a detailed snapshot of health. Its Q BioVault platform analyzes this information within a 60-minute session, including a whole body MRI, to identify and track significant changes in a patient's health over time. By correlating various data sources, the platform automatically highlights critical health changes, helping to detect early stages of disease before symptoms manifest.
Fountain Therapeutics is discovering and developing treatments for aging-associated diseases.
Fountain Therapeutics was founded with the belief that a future in which we live healthier lives longer is more desirable than one in which the company continues to be afflicted by the disease of aging. The company builds a transformative model of aging that re-creates many of the complex hallmark features of aging but in a laboratory dish. We are combining this powerful cellular model with the latest in artificial intelligence and computer vision to develop a disruptive unbiased platform for the identification of novel targets and potential therapeutics.
Arpeggio Biosciences, Inc. is a biotechnology company based in Boulder, Colorado, founded in 2017. It specializes in developing software that captures and analyzes cellular RNA activity through a unique combination of biological assays and machine learning algorithms. This technology allows for low-depth sequencing to generate high-resolution snapshots of cellular dynamics in response to drug treatments. By revealing the biological networks that influence a drug's function, Arpeggio's platform aids pharmaceutical and biotechnology companies in understanding the mechanisms behind therapeutics. The company’s approach enhances the identification of new drug targets and increases the likelihood of success in clinical advancements. Arpeggio Biosciences is composed of a diverse team of molecular biologists, computer scientists, and biotechnology enthusiasts dedicated to advancing the understanding of drug mechanisms.
Inflammatix, Inc. is a molecular diagnostics company based in Burlingame, California, established in 2016. The company specializes in developing rapid tests that analyze the immune system to address significant clinical and public health challenges, particularly in the diagnosis of acute bacterial and viral infections, as well as sepsis. Utilizing patent-pending biomarkers exclusively licensed from Stanford University, Inflammatix aims to create clinically actionable results through proprietary machine-learning algorithms. In addition to its focus on acute infections and sepsis, the company is expanding its diagnostics pipeline to include tests for tropical infections, autoimmune diseases, transplant rejection, and other medical conditions, ultimately assisting healthcare providers in making informed diagnostic decisions.
Deep Genomics Inc. is an artificial intelligence therapeutics company that focuses on developing individualized genetic medicines. Founded in 2014 and based in Toronto, Canada, the company utilizes advanced AI systems to enhance various stages of drug discovery and development, including target identification, lead optimization, toxicity evaluation, and trial design. Deep Genomics specializes in creating oligonucleotide therapies that address the genetic causes of diseases at the RNA and DNA levels. Its innovative AI-powered platform analyzes RNA biology to uncover new therapeutic targets and mechanisms that traditional methods cannot access, enabling the development of treatments for rare metabolic, ophthalmologic, and neurodegenerative disorders. The company recruits top talent in genomics, drug development, and AI to drive its mission of revolutionizing drug discovery.
EGenesis Inc. is a biotechnology company based in Cambridge, Massachusetts, with an additional office in New York. Founded in 2015, the company specializes in gene editing and genome engineering, focusing on the development of human-compatible organs, tissues, and cells for transplantation. EGenesis employs advanced gene editing techniques to create transplantable cells and solid organs, specifically targeting therapeutic applications in kidney and islet cell transplantation. By leveraging its innovative platform, the company aims to transform the field of organ transplantation, providing safe and effective solutions for patients with life-threatening diseases globally.
Korbit Technologies is focused on transforming education through its AI tutor, Korbi, which utilizes artificial intelligence to engage students in personalized learning experiences. The platform offers interactive exercises, conversations, quizzes, visual aids, and performance tracking tailored to individual learning profiles. Korbi aims to enhance educational outcomes by providing targeted pedagogical interventions and personalized feedback. In addition to its tutoring services, Korbit Technologies also offers a free machine learning course, catering to a broad audience that includes students, teachers, publishers, and companies. Founded in 2018 and headquartered in Montreal, Canada, Korbit Technologies is committed to delivering high-quality, accessible education that supports learners in improving their socio-economic status.
Karma Biotechnologies, Inc. develops therapies for autoimmune diseases. It offers Xavines, a therapeutic to treat autoimmunity, allergies, and food sensitivities. Karma Biotechnologies, Inc. was incorporated in 2019 and is based in Los Angeles, California.
Gen1E Lifesciences is a developer of a platform designed to accelerate cures for inflammatory and age-related diseases.The company's services include a pipeline of preclinical stage products that includes a P38 kinase inhibitor for the treatment of various inflammatory diseases, enabling medical researchers to optimize existing regulatory incentives, reduce the required R&D time and cost, truncate the time to exit and improve the success rate in receiving FDA approval and commercial success.
Encellin, Inc. is a biotechnology company based in San Francisco, California, founded in 2015. It specializes in developing innovative cell-based therapeutics, particularly focusing on a novel thin-film cell encapsulation device. This device utilizes advanced thin-film cell delivery technology, which encapsulates and replaces cells, allowing the enclosed cells to operate as smart molecular factories. Encellin's primary mission is to provide effective treatments for patients with chronic diseases, with an initial emphasis on Type 1 diabetes. The company is committed to advancing next-generation therapies through the expertise of its dedicated team.
Aguamarina Biomineria specializes in solutions based on green mining technology. Pamela Chavez Crooker founded it in 2015, with its headquarters in Antofagasta in Chile.
Overture Life, Inc. is a New York-based company that specializes in developing robotic technologies for in vitro fertilization (IVF) applications. Founded in 2017, Overture Life aims to transform embryology through its innovative reproduction automation technology. The company's products focus on automating key processes in IVF, including devices for automated cryopreservation and embryo testing services. These advancements enable fertility clinics to identify viable embryos prior to implantation, thereby assisting individuals and couples in their efforts to conceive.
Bionaut Labs is a biotechnology company that specializes in developing an intra-tissue navigation platform using nano and micro-robots for medical applications. Founded in 2016 and headquartered in California, Bionaut Labs focuses on creating a delivery mechanism that allows for anatomically precise navigation within the body. The company's innovative micro-robotic technology is designed to access any anatomical location, enabling medical professionals to perform complex surgical procedures remotely and without external incisions. This advancement is achieved through an advanced remote control and imaging system that accurately guides the robots to their targets, monitors their progress, and triggers the release of therapeutic payloads at the appropriate locations and times.
Pendulum Therapeutics Inc., a microbiome company, produces microbiome-targeted medical probiotics. It offers Pendulum Glucose Control, a medical probiotic for the dietary management of type 2 diabetes. The company also develops prebiotics to help feed the probiotic strains. It sells its products online. Pendulum Therapeutics Inc. was formerly known as Whole Biome Inc. and changed its name to Pendulum Therapeutics Inc. in July 2019. The company was incorporated in 2012 and is based in San Francisco, California.
Cellino Biotech, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2017. It specializes in intracellular delivery lasers and nanotechnology specifically for gene editing applications. The company has developed an AI-guided laser editing platform that automates the generation of personalized, autologous cell therapies, significantly reducing the development time of engineered cells from years to weeks. By integrating advanced tools from optics, biology, and computation, Cellino makes stem cell differentiation a digital process, allowing healthcare providers to efficiently produce functionally mature cells at scale. This innovative approach aims to enhance the accessibility of life-saving medicines for patients.
Prellis Biologics is building human tissues for drug development, and ultimately, developing human organs for transplantation. Bioprinting vascularized human tissue and organs will revolutionize healthcare. Prellis Biologics' technology leverages massive gains in print speed and resolution to break the microvasculature barrier.
BioAge Labs, Inc. is a biotechnology company focused on developing therapies for aging and age-related diseases. The company utilizes a proprietary systems biology and artificial intelligence platform to identify crucial drug targets that influence aging, leveraging extensive datasets to uncover the molecular drivers behind age-related conditions. BioAge Labs offers several drug candidates, including BGE-117, a hypoxia-inducible factor prolyl hydroxylase inhibitor aimed at treating multiple diseases of aging by activating HIF-1 target genes linked to various biological processes such as tissue regeneration and vascular remodeling. Another candidate, BGE-175, is an orally administered inhibitor that targets the prostaglandin D2 DP1 signaling pathway, which is associated with increased mortality risk and susceptibility to infections. Founded in 2015 and based in Richmond, California, BioAge Labs is committed to advancing the understanding and treatment of aging-related health issues.
Loop Genomics is a platform technology for long-read DNA sequencing. Loop Genomics technology transforms short-read DNA sequencers into high-throughput, long-read, single-molecule DNA sequencing machines. Loop Genomics long-read DNA sequencing technology provides phased sequencing solutions across a diverse repertoire of research and clinical applications. Sequencing of partial rRNA gene sequences results in reduced phylogenetic resolution. Full-length, high-throughput, phased sequencing that covers all 16S variable regions is becoming the gold standard for profiling the microbiome. Achieve the highest resolution microbial community profiling with long-read, next-generation sequencing of the microbiome. Characterizing polymorphisms in HLA genes inside and outside of the protein-coding regions is important for organ transplantation compatibility testing and for strengthening causality association studies. The length of homologous sequences between HLA alleles extends beyond the capabilities of short-read sequencing platforms, resulting in diploid ambiguities and a reliance on imputation. Sequence full-length HLA DNA and/or RNA with phased, high throughput, long-read sequencing that resolves allelic discrimination and diploid ambiguity. Viral genetic variability is a major determinant of viral drug resistance and viral vaccine efficacy. Accurately mapping viral genetic variability is a critical step in choosing the optimal course of therapy and developing efficacious vaccines. Key mutations are typically located throughout long stretches of viral genomes, making the retrieval of critical phased data challenging using short-read sequencing technology. Use phased, high-throughput DNA sequencing technology to map key mutations at the quasi-species level and generate a complete phased map of viral populations.
Clear Labs, Inc. is a food analytics company based in Menlo Park, California, founded in 2013. The company offers a comprehensive food analytics platform that utilizes next-generation sequencing to analyze the molecular contents of foods and ingredients. This platform provides food manufacturers, suppliers, and retailers with crucial transparency across supply chains, testing products for authenticity, contaminants, allergens, and various other factors such as GMOs, heavy metals, and nutrition. Clear Labs also focuses on simplifying complex diagnostics for clinical and applied markets, combining DNA sequencing, robotics, and cloud-based analytics to improve accuracy and accelerate outcomes. By delivering insights into food safety and quality, Clear Labs aims to enhance understanding and management of potential health risks associated with food products and emerging pathogens.
Nebula Genomics, founded in 2016 and based in San Francisco, California, is a company focused on human genome sequencing and health data. It aims to create a comprehensive and trusted marketplace for genomic and health data, facilitating access for consumers, researchers, and the medical community. Utilizing blockchain technology, Nebula Genomics empowers individuals to control their genomic data while receiving compensation for its use. The marketplace aggregates extensive genetic information, which researchers can analyze to enhance drug development and streamline clinical trials, ultimately contributing to personalized medicine. The company's innovative DNA sequencing technology allows for the examination of all genes, regulatory regions, the Y chromosome, and mitochondrial DNA, enabling clients to explore genetic variants comprehensively. Nebula Genomics was co-founded by Harvard genomics pioneer George Church and has received backing from notable investors.
Opentrons is a company focused on developing pipetting robot technology to automate laboratory experiments. By utilizing open-source principles and programming in Python, Opentrons creates automated lab equipment that streamlines various scientific processes. Their product offerings encompass lab robots, workstations, hardware modules, consumables, reagents, and labware, all designed to enhance the efficiency and accuracy of research. This automation helps scientific researchers reduce human error and expedite their experimental workflows, making lab work faster and less labor-intensive.
Viome, Inc. is a biotechnology company based in Bellevue, Washington, that specializes in wellness monitoring through at-home clinical-grade testing kits. Founded in 2016, the company combines analyses of blood, urine, saliva, and stool samples to create detailed profiles of an individual's biochemistry and gut microbiome. Utilizing proprietary RNA sequencing technology, Viome assesses the microbial communities in the digestive system and provides users with personalized insights related to their health. The findings are integrated into a smartphone application that offers tailored recommendations for diet and lifestyle adjustments aimed at preventing and reversing chronic diseases. Viome markets its products through various distributors and online platforms, operating as a subsidiary of BlueDot LLC.
Opentrons is a company focused on developing pipetting robot technology to automate laboratory experiments. By utilizing open-source principles and programming in Python, Opentrons creates automated lab equipment that streamlines various scientific processes. Their product offerings encompass lab robots, workstations, hardware modules, consumables, reagents, and labware, all designed to enhance the efficiency and accuracy of research. This automation helps scientific researchers reduce human error and expedite their experimental workflows, making lab work faster and less labor-intensive.
Opentrons is a company focused on developing pipetting robot technology to automate laboratory experiments. By utilizing open-source principles and programming in Python, Opentrons creates automated lab equipment that streamlines various scientific processes. Their product offerings encompass lab robots, workstations, hardware modules, consumables, reagents, and labware, all designed to enhance the efficiency and accuracy of research. This automation helps scientific researchers reduce human error and expedite their experimental workflows, making lab work faster and less labor-intensive.
BioConsortia, Inc. is an agricultural biotechnology company focused on enhancing agricultural yields through the discovery, development, and commercialization of microbial consortia seed treatments and soil additives. Founded in 2014 and headquartered in Davis, California, the company employs a proprietary Advanced Microbial Selection process to identify beneficial microbial combinations that optimize plant traits. These microbial consortia are designed to improve fertilizer utilization, enhance root mass, accelerate crop development, and provide resistance to biotic and abiotic stresses. BioConsortia's products aim to leverage the complex interactions between soil and plant-associated microbes and the crop genome to deliver significant agricultural benefits. The company also maintains research and development facilities in New Zealand and the United States, furthering its commitment to innovative agricultural solutions.
Atomwise, Inc. specializes in deep learning artificial intelligence technology aimed at small molecule drug discovery. The company leverages its proprietary AI platform, AtomNet, which contains over 16 billion molecules for virtual screening, to enhance the speed and accuracy of drug discovery processes. This technology employs a statistical approach to predict the binding of small molecules to proteins, aiding in drug hit discovery, binding affinity prediction, and toxicity detection. Atomwise collaborates on numerous projects each year with major pharmaceutical and agrochemical companies, as well as over 200 universities and hospitals across 40 countries. Founded in 2012 and based in San Francisco, Atomwise was previously known as Chematria, Inc. before rebranding in 2015.
Q Bio, Inc. is a healthcare technology company that has developed a clinically relevant whole body analytics platform aimed at providing comprehensive health assessments. Founded in 2015 and based in Redwood City, California, Q Bio combines advanced non-invasive imaging, genetics, biochemistry, vital signs, and an individual's medical history to create a detailed snapshot of health. Its Q BioVault platform analyzes this information within a 60-minute session, including a whole body MRI, to identify and track significant changes in a patient's health over time. By correlating various data sources, the platform automatically highlights critical health changes, helping to detect early stages of disease before symptoms manifest.
Mirvie is a biotech company that creates precise, actionable, and non-invasive tests for maternal-fetal health. The company delivers insights to moms and families to make pregnancy safe. It was founded in 2018 by Maneesh Jain and is headquartered in South San Francisco, California, United States.
Eligo Bioscience S.A.S is a biotechnology company based in Paris, France, that specializes in developing Eligobiotics, a novel class of antimicrobials designed to target specific bacteria based on their genetic makeup. Founded in 2014, Eligo Bioscience utilizes a combination of the CRISPR/Cas system and engineered phage capsids to create antibiotics aimed at treating diseases associated with the human microbiome and resistant pathogens. Their innovative approach allows for the precise eradication of virulent bacteria, addressing the growing challenge of antibiotic resistance. The potential applications of their technology extend beyond therapeutics to include areas such as cosmetics and biodefense, positioning Eligo Bioscience at the forefront of next-generation antimicrobial development.
Deep Genomics Inc. is an artificial intelligence therapeutics company that focuses on developing individualized genetic medicines. Founded in 2014 and based in Toronto, Canada, the company utilizes advanced AI systems to enhance various stages of drug discovery and development, including target identification, lead optimization, toxicity evaluation, and trial design. Deep Genomics specializes in creating oligonucleotide therapies that address the genetic causes of diseases at the RNA and DNA levels. Its innovative AI-powered platform analyzes RNA biology to uncover new therapeutic targets and mechanisms that traditional methods cannot access, enabling the development of treatments for rare metabolic, ophthalmologic, and neurodegenerative disorders. The company recruits top talent in genomics, drug development, and AI to drive its mission of revolutionizing drug discovery.
Karius, Inc. is a life sciences company dedicated to generating genomic insights for infectious diseases. It offers the Karius Test, a non-invasive blood test that utilizes sequencing of microbial cell-free DNA to identify and quantify various pathogens, including bacteria, DNA viruses, fungi, and parasites. This test is particularly useful for diagnosing complicated pneumonia, infections in immunocompromised patients, and endocarditis. Karius also provides laboratory services for pathogen biomarker detection tailored for biopharmaceutical companies. Founded in 2014, the company is based in Redwood City, California, with an additional office in Menlo Park. Its laboratory holds CLIA certification and CAP accreditation, allowing it to conduct high-complexity clinical laboratory testing to support rapid clinical decision-making.
Viome, Inc. is a biotechnology company based in Bellevue, Washington, that specializes in wellness monitoring through at-home clinical-grade testing kits. Founded in 2016, the company combines analyses of blood, urine, saliva, and stool samples to create detailed profiles of an individual's biochemistry and gut microbiome. Utilizing proprietary RNA sequencing technology, Viome assesses the microbial communities in the digestive system and provides users with personalized insights related to their health. The findings are integrated into a smartphone application that offers tailored recommendations for diet and lifestyle adjustments aimed at preventing and reversing chronic diseases. Viome markets its products through various distributors and online platforms, operating as a subsidiary of BlueDot LLC.
Developer of immunity-boosting proteins designed to improve the lives of people who suffer from food allergies and gluten-related disorders. The company's technology uses artificial intelligence, immunology, computational biology, and protein engineering to make safe proteins that do not trigger an immune response, enabling physicians to prescribe to people products that are safe to consume.
Guardant Health, Inc. is a precision oncology company based in Redwood City, California, specializing in liquid biopsy tests and analytics for cancer detection and treatment. The company provides advanced testing solutions, including Guardant360, a molecular diagnostic test that analyzes numerous cancer-related genes, and GuardantOMNI, which offers a comprehensive gene panel for immuno-oncology research. Additionally, Guardant Health has developed LUNAR-1 for detecting minimal residual disease in cancer survivors and is working on LUNAR-2 for early cancer detection in high-risk individuals. The company also supports biopharmaceutical companies and medical institutions by offering companion diagnostic development, clinical trial referrals, and liquid biopsy testing services. Guardant Health's innovations aim to address unmet needs in oncology and enhance patient health through advanced technology and research collaborations. The company was incorporated in 2011 and continues to lead in liquid-based cancer testing for both clinical and research applications.
Ontera develops a hand-held point of use diagnostic platform that examines DNA and RNA, and analytes (proteins, viruses, antibodies, etc) from any life form. Use in human and animal diagnostics, agriculture, food safety testing, environmental monitoring, and more. Our platforms use silicon nanopore chips and proprietary biochemistry to accurately detect and differentiate single molecules. We will help transform point-of-care testing and third generation sequencing.
Inflammatix, Inc. is a molecular diagnostics company based in Burlingame, California, established in 2016. The company specializes in developing rapid tests that analyze the immune system to address significant clinical and public health challenges, particularly in the diagnosis of acute bacterial and viral infections, as well as sepsis. Utilizing patent-pending biomarkers exclusively licensed from Stanford University, Inflammatix aims to create clinically actionable results through proprietary machine-learning algorithms. In addition to its focus on acute infections and sepsis, the company is expanding its diagnostics pipeline to include tests for tropical infections, autoimmune diseases, transplant rejection, and other medical conditions, ultimately assisting healthcare providers in making informed diagnostic decisions.
EGenesis Inc. is a biotechnology company based in Cambridge, Massachusetts, with an additional office in New York. Founded in 2015, the company specializes in gene editing and genome engineering, focusing on the development of human-compatible organs, tissues, and cells for transplantation. EGenesis employs advanced gene editing techniques to create transplantable cells and solid organs, specifically targeting therapeutic applications in kidney and islet cell transplantation. By leveraging its innovative platform, the company aims to transform the field of organ transplantation, providing safe and effective solutions for patients with life-threatening diseases globally.
Clear Labs, Inc. is a food analytics company based in Menlo Park, California, founded in 2013. The company offers a comprehensive food analytics platform that utilizes next-generation sequencing to analyze the molecular contents of foods and ingredients. This platform provides food manufacturers, suppliers, and retailers with crucial transparency across supply chains, testing products for authenticity, contaminants, allergens, and various other factors such as GMOs, heavy metals, and nutrition. Clear Labs also focuses on simplifying complex diagnostics for clinical and applied markets, combining DNA sequencing, robotics, and cloud-based analytics to improve accuracy and accelerate outcomes. By delivering insights into food safety and quality, Clear Labs aims to enhance understanding and management of potential health risks associated with food products and emerging pathogens.
Genalyte, Inc. is a clinical and diagnostic life science company based in San Diego, California, specializing in rapid diagnostic testing solutions. Founded in 2007, Genalyte has developed an innovative technology platform that utilizes silicon photonic biosensors to quantify biomolecular interactions, such as those between antibodies and proteins. This platform, known as the Maverick, allows for the direct measurement of protein binding and nucleic acid hybridization. Genalyte's technology is employed by healthcare providers, pharmaceutical companies, and academic researchers to monitor autoimmune diseases, screen for cancer biomarkers, detect anti-drug antibodies, and test for infectious agents, including Ebola. The company aims to enhance patient care by enabling rapid diagnostics, with tests typically completed in under thirty minutes, and providing mobile laboratory solutions for real-time diagnostics.
BioConsortia, Inc. is an agricultural biotechnology company focused on enhancing agricultural yields through the discovery, development, and commercialization of microbial consortia seed treatments and soil additives. Founded in 2014 and headquartered in Davis, California, the company employs a proprietary Advanced Microbial Selection process to identify beneficial microbial combinations that optimize plant traits. These microbial consortia are designed to improve fertilizer utilization, enhance root mass, accelerate crop development, and provide resistance to biotic and abiotic stresses. BioConsortia's products aim to leverage the complex interactions between soil and plant-associated microbes and the crop genome to deliver significant agricultural benefits. The company also maintains research and development facilities in New Zealand and the United States, furthering its commitment to innovative agricultural solutions.
Siolta Therapeutics is a developer of human microbiome therapeutics intended to prevent and treat inflammatory diseases. The company leverages its deep knowledge of the developing gut microbiome and its role in promoting immune tolerance to develop targeted microbial therapeutics and companion diagnostics for the prevention and treatment of inflammatory diseases, enabling medical researchers to harness information from human microbiome studies to design next-generation microbial therapeutics to prevent inflammatory processes.
Color is a population health technology company founded in 2014 and based in Burlingame, California. It focuses on providing technology and infrastructure for large-scale health initiatives, making advanced healthcare services accessible and cost-effective. Color's Population Genomics Platform offers modular and comprehensive solutions designed to help health systems, employers, and research institutions develop and implement effective population health programs. The company combines innovative technology with specialized laboratory infrastructure and clinical services, facilitating various aspects of health programs, including strategy, participant engagement, genetic testing, data management, and clinical reporting. Color’s partnerships with organizations such as the National Institutes of Health and Verily enhance its capabilities, enabling it to deliver precision health programs that address the challenges of traditional healthcare access and costs.
Luminostics, Inc. is a healthcare technology company based in Houston, Texas, established in 2015. The company has developed a smartphone-based adaptor that enables users to conduct molecular-level health assessments through do-it-yourself disease testing. This innovative solution allows healthcare professionals and consumers to obtain health information quickly, with tests that can be completed in just 15 minutes. By combining mobile technology with accessible testing methods, Luminostics aims to enhance the way individuals monitor and manage their health.
Pendulum Therapeutics Inc., a microbiome company, produces microbiome-targeted medical probiotics. It offers Pendulum Glucose Control, a medical probiotic for the dietary management of type 2 diabetes. The company also develops prebiotics to help feed the probiotic strains. It sells its products online. Pendulum Therapeutics Inc. was formerly known as Whole Biome Inc. and changed its name to Pendulum Therapeutics Inc. in July 2019. The company was incorporated in 2012 and is based in San Francisco, California.
Guardant Health, Inc. is a precision oncology company based in Redwood City, California, specializing in liquid biopsy tests and analytics for cancer detection and treatment. The company provides advanced testing solutions, including Guardant360, a molecular diagnostic test that analyzes numerous cancer-related genes, and GuardantOMNI, which offers a comprehensive gene panel for immuno-oncology research. Additionally, Guardant Health has developed LUNAR-1 for detecting minimal residual disease in cancer survivors and is working on LUNAR-2 for early cancer detection in high-risk individuals. The company also supports biopharmaceutical companies and medical institutions by offering companion diagnostic development, clinical trial referrals, and liquid biopsy testing services. Guardant Health's innovations aim to address unmet needs in oncology and enhance patient health through advanced technology and research collaborations. The company was incorporated in 2011 and continues to lead in liquid-based cancer testing for both clinical and research applications.